Aeglea Biotherapeutics competitors

Aeglea Biotherapeutics Competitors include Aptevo Therapeutics, Immune Design, XBiotech and ImmunoGen.
Add company...
Aeglea Biotherapeutics
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
XBiotech
XBiotech is a biopharmaceutical company developing first-in-class antibody therapies.
ImmunoGen
ImmunoGen engages in the research and development of antibody-based anticancer therapeutics using its targeted antibody payload technology.
Founding Date
Founding Date
2013
Founding Date
2016
Founding Date
2008
Founding Date
2005
Founding Date
1981
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Austin, US HQ
Locations
Seattle, US HQ
Locations
Seattle, US HQ
South San Francisco, US
Locations
Austin, US HQ
Locations
Waltham, US HQ
Brentwood, US
Norwood, US
Employees
Employees
4518% increase
Employees
118
Employees
50
Employees
56
Employees
308
Valuation ($)
Valuation ($)
199.5 m
Valuation ($)
98.4 m
Valuation ($)
134.4 m
Valuation ($)
116.4 m
Valuation ($)
1.1 b
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
163
Twitter followers
430

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$14.7m (FY, 2017)
Revenue (est.)
$7.2m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$115.4m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
$5m (FY, 2017)
Cost of goods
$84k (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$9.6m (FY, 2017)
Gross profit
$7.1m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($27.2m) (FY, 2017)
Net income
$7m (FY, 2017)
Net income
($51.9m) (FY, 2017)
Net income
($50.7m) (FY, 2016)
Net income
($96m) (FY, 2017)

Operating

Phase I Trials Products
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Aptevo Therapeutics
HQ
Seattle, US
Employees
118

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.

View company
Immune Design
HQ
Seattle, US
Employees
50

Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.

View company
XBiotech
HQ
Austin, US
Employees
56

XBiotech is a biopharmaceutical company developing first-in-class antibody therapies.

View company
ImmunoGen
HQ
Waltham, US
Employees
308

ImmunoGen engages in the research and development of antibody-based anticancer therapeutics using its targeted antibody payload technology.

View company